Title : Assessment of effectiveness of bupivacaine trigger-point injections in trapezius myofascial pain syndrome: A retrospective study
Abstract:
Background: Trapezius Myofascial Pain Syndrome (MPS) is a frequent cause of chronic neck and shoulder pain, contributing to disability and reduced quality of life. Trigger-Point Injections (TPIs) with local anesthetics are widely used, yet evidence for bupivacaine in this context remains limited.
Objective: To evaluate the effectiveness and safety of bupivacaine TPIs in trapezius MPS.
Methods: A retrospective review of 69 patients with clinically diagnosed trapezius MPS who received 0.25% bupivacaine TPIs was conducted at a tertiary care center (Aug 2023–Feb 2025). Pain intensity Visual Analog Scale (VAS) and disability Neck Pain and Disability Index (NPDI) were assessed at baseline, immediately post-injection, 2 weeks, and 1 month. Repeated measures ANOVA with post-hoc analysis determined statistical significance.
Results: Mean VAS scores improved significantly from 6.10 at baseline to 2.64 at one month (p < 0.001). Similarly, mean NPD scores decreased from 31.7 to 12.8 (p < 0.001). The majority (94.2%) reported no adverse effects, while minor self-limiting events occurred in 4 patients. Overall, 70.6% expressed satisfaction with the intervention.
Conclusion: Bupivacaine TPIs are effective and safe for pain reduction and functional improvement in trapezius MPS, offering a pragmatic, low-cost treatment option in clinical practice.
Keywords: Trigger-Point Injections, Bupivacaine, Myofascial Pain Syndrome, Neck Pain, Rehabilitation
